119 related articles for article (PubMed ID: 2468457)
1. Cytotoxicity of cisplatin and carboplatin used alone and in combination with the other anticancer drugs in the mouse embryo C3H10T1/2 cell line.
Hussain SS; Amer MH; Hannan MA
Chemotherapy; 1988; 34(6):504-11. PubMed ID: 2468457
[TBL] [Abstract][Full Text] [Related]
2. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.
Fournier C; Hecquet B; Bastian G; Khayat D
Cancer Chemother Pharmacol; 1992; 29(6):461-6. PubMed ID: 1568289
[TBL] [Abstract][Full Text] [Related]
3. Mutagenicity of cisplatin and carboplatin used alone and in combination with four other anticancer drugs.
Hannan MA; al-Dakan AA; Hussain SS; Amer MH
Toxicology; 1989 Apr; 55(1-2):183-91. PubMed ID: 2652378
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Forastiere AA; Metch B; Schuller DE; Ensley JF; Hutchins LF; Triozzi P; Kish JA; McClure S; VonFeldt E; Williamson SK
J Clin Oncol; 1992 Aug; 10(8):1245-51. PubMed ID: 1634913
[TBL] [Abstract][Full Text] [Related]
5. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Huang GC; Liu SY; Lin MH; Kuo YY; Liu YC
Jpn J Clin Oncol; 2004 Sep; 34(9):499-504. PubMed ID: 15466821
[TBL] [Abstract][Full Text] [Related]
6. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
[TBL] [Abstract][Full Text] [Related]
7. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
8. [Experimental study on combination chemotherapy with platinum compounds and 5-fluorouracil].
Furukawa S; Yoshida T; Tukuda M; Yanoma S; Ryo I; Miyata K; Kubota A; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):419-22. PubMed ID: 2649008
[No Abstract] [Full Text] [Related]
9. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
Dorie MJ; Brown JM
Cancer Chemother Pharmacol; 1997; 39(4):361-6. PubMed ID: 9025778
[TBL] [Abstract][Full Text] [Related]
10. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations.
Tapazoglou E; Polin L; Corbett TH; al-Sarraf M
Invest New Drugs; 1988 Dec; 6(4):259-64. PubMed ID: 3068184
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the in vitro cytotoxicity of seven anticancer drugs by protein synthesis inhibition using sparsomycin.
Zylicz Z; Hofs HP; Wagener DJ; Van Rennes H; Wessels JM; van den Broek LA; Ottenheijm HC
Anticancer Res; 1989; 9(6):1835-40. PubMed ID: 2483308
[TBL] [Abstract][Full Text] [Related]
13. Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ.
Grau C; Overgaard J
Cancer Chemother Pharmacol; 1992; 30(4):277-80. PubMed ID: 1643695
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study of CF chemotherapy, combined with another one chemotherapeutic drug against head and neck cancer cell lines].
Tsukuda M; Mochimatsu I; Kokatsu T; Ito K; Furukawa S; Inoue T; Watanabe S; Sawaki S
Gan To Kagaku Ryoho; 1992 Apr; 19(4):553-6. PubMed ID: 1373052
[No Abstract] [Full Text] [Related]
15. Comparisons of carboplatin and cisplatin as potentiators of 5-fluorouracil and radiotherapy in the mouse L1210 leukaemia model.
Dionet CA; Rapp M; Tchirkov A
Anticancer Res; 2002; 22(2A):721-5. PubMed ID: 12014642
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
18. Tumoricidal interactions of hyperthermia with carboplatin, cisplatin and etoposide.
Cohen JD; Robins HI; Schmitt CL
Cancer Lett; 1989 Mar; 44(3):205-10. PubMed ID: 2647285
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.
Seki K; Yoshikawa H; Shiiki K; Hamada Y; Akamatsu N; Tasaka K
Cancer Chemother Pharmacol; 2000; 45(3):199-206. PubMed ID: 10663637
[TBL] [Abstract][Full Text] [Related]
20. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
